Average operating hashrate of 3.9 EH/s
Mackenzie (50MW to 80MW) infrastructure expansion on track
Construction & energization at Childress site continues
Limited recourse equipment financing and Bitmain prepayment update
Merk Reports Positive CHMP Opinion For KEYTRUDA In Combo With Chemo for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1
Recommendation Based on Data From Phase 3 KEYNOTE-355 Trial
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the Committee for Medicinal Products
